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Abstract 
Multiple myeloma management has undergone profound changes in the past thanks to advances in 
our understanding of the disease biology and improvements in treatment and supportive care 
approaches. This article presents recommendations of the European Myeloma Network for newly 
diagnosed patients based on the GRADE system for level of evidence. All patients with 
symptomatic disease should undergo risk stratification to classify patients for International Staging 
System stage (level of evidence: 1A) and for cytogenetically defined high- versus standard-risk 
groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in 
medically fit patients remains the standard of care (1A). Induction therapy should include a triple 
combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with 
cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be 
considered for young patients with high-risk disease and preferably in the context of a clinical trial 
(2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and 
possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, 
especially for patients who failed excellent response after autologous stem cell transplantation (2A). 
Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care 
for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide 
maintenance increases progression-free survival, but overall survival data are needed. New data 
from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached 
its primary end point of a statistically significant improvement in progression-free survival as 
compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of 
lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B). 
Introduction 
The outcome for patients with multiple myeloma (MM) has improved substantially over the past 20 
years due to several therapeutic advances. High-dose therapy (HDT) with autologous stem cell 
transplantation (ASCT) was developed in the 1980s and is currently considered the standard front-
line treatment for younger and fit patients.
1–3
 The introduction of novel agents, thalidomide, 
lenalidomide, bortezomib, but also the availability of various others, such as 3rd-generation 
immunomodulatory drugs (IMiDs; pomalidomide), novel proteasome inhibitors, including 
carfilzomib, ixazomib and oprozomib, antibodies, such as elotuzumab (target: CS1), daratumumab 
and SAR650984 (CD38), siltuximab (IL-6), tabalumab (BAFF), denosumab (RANKL), 
romosozumab (sclerostin), Bruton tyrosine kinase, heat shock protein inhibitors and other 
innovative phase I/II agents have changed or will alter the therapeutic scenario in several ways.
4–7
 
Moreover, cereblon (CRBN) has been identified as a possible biomarker for the assessment of 
clinical efficacy of IMiDs, although this is still a subject of controversy and CRBN testing needs to 
be standardized.
8,9
 The predictive role of CRBN was assessed in the HOVON/GMMG trial, where 
higher CRBN expression was associated with better survival and clinical efficacy of thalidomide.
9
 
Novel agents have been incorporated as induction regimens with the objective of increasing the 
response prior to ASCT, and as consolidation or maintenance treatment to increase the depth of 
response and prolong the duration of response. The current goal of ASCT with inclusion of novel 
agents is improvement in quality of response, extension of progression-free survival (PFS) and, 
importantly, overall survival (OS).
10
 Some experts even consider MM a potentially curable disease, 
challenging this approach with earlier treatment, more intensive therapy approaches, risk-adapted 
strategies and use of serial biological examinations guiding treatment decisions.
3,11
 This ‘cure 
versus control’ debate on whether MM patients should be treated with an intensive multi-drug 
strategy targeting complete response (CR), or a sequential disease control approach that emphasizes 
quality of life (QoL), toxicity avoidance and OS has not been solved and may be different for the 
various molecular MM subtypes.
12
 International initiatives and collaborations under the auspices of 
the European Myeloma Network (EMN), the International Myeloma Working Group (IMWG) and 
others co-operate in large trials translating insights from innovative trials into clinical practice. The 
EMN reviewed all available evidence and provides below recommendations for the management of 
newly diagnosed MM. 
Methodology 
These recommendations were developed by an interdisciplinary panel of clinical experts on MM 
based on evidence of published data including randomized clinical studies, meta-analyses, 
systematic reviews and other available published clinical studies through August 2013. Expert 
consensus was used to suggest recommendations where there were no sufficient data. Grades of 
recommendations were assigned using the GRADE criteria (Table 1). The recommendations were 
circulated among each panel member who made their comments, while the recommendations were 
also discussed in the EMN Trialist meeting (Baveno, Italy, 15–16 September 2013). The manuscript 
subsequently underwent two rounds of revision until the EMN experts reached a consensus. 
 
 
 
 
 
 
 
 
 
 
Table 1. Grade recommendations for grading levels of evidence 
 
Diagnosis of symptomatic myeloma 
It is important to establish a diagnosis of symptomatic MM requiring therapy. MM always arises 
from an asymptomatic precursor condition, either monoclonal gammopathy of undetermined 
significance (MGUS) or smoldering multiple myeloma (SMM).
13,14
 Patients with MGUS and SMM 
should be followed carefully for the development of myeloma-related organ or tissue impairment 
(ROTI), the most common being hypercalcemia, renal failure, anemia and bone disease (CRAB). It 
is critical that the clinician determines whether symptoms are related to the MM, since there are 
numerous examples of false attribution of symptoms to MM, when in fact other conditions account 
for hypercalcemia, such as primary hyperparathyroidism or anemia secondary to iron-deficiency.
15
 
MGUS with renal impairment (RI) has been recognized as an independent entity and named 
‘monoclonal gammopathy of renal significance’ (MGRS).16 Similar to MGRS, small PC clones, 
although not fulfilling the criteria of MM, can give rise to clinically relevant extrarenal organ 
damage, that should be diagnosed and treated early and appropriately, e.g. AL-amyloidosis, light 
chain deposition disease, POEMS syndrome, cold hemagglutinine disease or sleromyxedema.
17
 
Since a critical determinant of survival in most malignancies is early detection, the timely diagnosis 
and treatment in MM is currently being explored. Nevertheless, early detection is not applicable to 
MM, because there is no current definition of ‘early myeloma’. Because of this, treatment protocols 
do not adapt therapy on the basis of tumor burden, but rather on that of CRAB criteria, reflecting 
substantial disease burden that is considered more difficult to eradicate than lower tumor burden. 
MM is consistently preceded by a precursor state, rendering the effects of early intervention 
testable; namely, whether MM will evolve. Early intervention is currently not recommended outside 
a clinical trial, because subjects with myeloma precursor diseases do not all develop overt MM. 
Notably, the distinction between SMM and MM is not based on clear biological differences, and 
there is a significant overlap. Determination of end-organ damage often requires subjective 
interpretation of insensitive modalities, such as skeletal surveys. Therefore, most tertiary institutions 
use more sensitive tests, e.g. whole-body computed tomography (CT) or magnetic resonance 
imaging (MRI). Alternate proposals are to classify cases of MM with limited organ damage and 
SMM with the highest risk of progression as ‘early myeloma’. However, this concept requires 
reliable biological tools to distinguish cases of SMM that are ‘MGUS-like’ versus those that are 
more ‘MM-like’. Two groups have retrospectively identified variables that identify SMM patients 
at the highest risk of progression, but neither identified with any certainty subjects who will 
progress to MM.
18
 In addition, risk stratification models for SMM have a low concordance rate with 
each other.
19
 Therefore, without precise tools for patient selection, the decision for early 
intervention concentrates on the perceived assessment of risk versus benefit. The Spanish MM-
group has recently shown that HR SMM patients may benefit from early therapy with lenalidomide 
as induction and subsequent maintenance therapy versus observation,
20
 intruguing results which 
need to be confirmed in subsequent trials. Future well-designed correlative studies are needed to 
assess the advantages and disadvantages of early treatment, including long-term adverse effects or 
selection of more aggressive clones followed by non-responsive disease (Figure 1).
11,21
 
 
Figure 1. Initiation and progression of MM. MGUS is an indolent, asymptomatic condition and pre-
malignant precursor form of MM, that may progress into SMM and symptomatic myeloma, and eventually 
(with a more aggressive disease courses - into extramedullary disease), such as plasma cell leukemia (PCL). 
During this disease progression, genetic events may accumulate with tumor diversity and genetic lesions 
increasing, these events evolving through clonal selection. Adapted with kind permission of G. Morgan.21 
The standard investigative workup for patients with suspected MM has been underlined by the 
IMWG report recommending measurement of the monoclonal protein, serum-free light chain assay, 
bone marrow (BM) aspiration and/or biopsy along with demonstration of clonality of PCs, FISH-
cytogenetics with evaluation of del17p, t(4;14) and t(14;16) as mandatory abnormalities and of 
amp1q21 and del1p as optional parameters. The skeletal survey (with more sensitive imaging via 
CT, MRI and positron emission tomography (PET)) provides valuable diagnostic and prognostic 
information, both at initial diagnosis and at relapse.
22
 
Prognosis and current risk factors 
Prognosis in MM is based on both the ISS and chromosomal abnormalities (Table 2). The ISS is a 
simplified staging system incorporating beta (β)2-microglobulin and serum albumin, and reflects 
tumor burden, renal function and host fitness. Additionally, BM karyotype, translocations, 
chromosome number and gene expression profiling have prognostic value.
23
 Currently, no specific 
therapies for particular molecular MM subgroups can be recommended based on results of 
prospective clinical trials, albeit two groups are pursuing this approach.
24,25
 Risk stratification has 
skillfully been described by the IMWG consensus panel.
26
 
 
Table 2. Prognostic factors in MM. 
 
Recommendation: All patients should undergo risk stratification to classify patients for ISS stage 
(1A) and also for cytogenetically defined HR versus SR groups, i.e. by FISH (2B). Retrospective 
analyses suggest that incorporation of bortezomib into the ASCT sequence may translate into 
extended PFS, and possibly OS, for patients who carry t(4;14) and/or del(17p) (2B).
27–29
 
Recommended approach to initial therapy 
The current paradigm for treatment of newly diagnosed MM is divided into three phases: induction, 
consolidation, and maintenance. The approach to each phase of therapy is individualized based on 
the features of the disease, age, comorbidities and personal preferences. Patients with renal failure 
(RF) from myeloma should start induction as soon as possible with bortezomib and dexamethasone-
based regimens. In addition, MM patients with RF should avoid nephrotoxic drugs and maintain 
euvolemia. The role of mechanical removal of free light chains by plasmapheresis or high cut-off 
dialysis in the management of myeloma-related RF remains unclear, and is currently assessed in 
clinical trials in conjunction with chemotherapy. Several studies revealed significant activity of 
rapidly acting bortezomib-based regimens, such as bortezomib-doxorubicin-dexamethasone (PAD), 
bortezomib-melphalan-prednisone (VMP) or bortezomib-melphalan-prednisone-thalidomide 
followed by bortezomib-thalidomide (VMPT-VT)). Both latter combinations were tested in 
untreated patients with RI: RI reversed in 16 of 63 (25%) patients receiving VMPT-VT versus 31 of 
77 (40%) with VMP, suggesting that the multi-drug combination VMPT-VT had no advantage in 
RI reversal over VMP, although it was superior with normal RF and moderate RI.
30
 Moreover, 
analgesia and bisphosphonates for painful bone lesions should be started. Consultation with an 
orthopedic oncologist for bone lesions at HR of fracture may be needed along with local 
radiotherapy to promptly ameliorate localized bone pain. Hypercalcemia should be managed with 
intravenous fluids and bisphosphonates. 
Recommendations for patients who are eligible for HDT and ASCT 
Induction regimens usually contain 3 of the 4 classes of drugs: corticosteroids, IMiDs, proteasome 
inhibitors and alkylating agents (Table 3).
31
 The goal of induction therapy is to reduce the myeloma 
burden, improve symptoms and allow for successful stem cell collection. Patients who are 
transplant candidates should not receive prolonged (>4–6 cycles) induction in order to ease stem 
cell harvest. Induction therapy can be considered as either two-or three-drug induction regimens. 
Although the three-drug induction regimens result in higher response rates, they are also 
accompanied by increased toxicity. In general, VD, VTD, PAD or others can be used as initial 
therapy for 3 or 4 cycles followed by stem cell harvest and ASCT (Table 3 and Figure 2).
31,32
 Four-
drug combinations, as tested in the EVOLUTION trial with bortezomib (V), dexamethasone (D), 
lenalidomide (R) or cyclophosphamide (C) as VDC, VDR and VDCR, have yielded similar PFS 
and OS, but four-drug combinations induced more side effects, so that VDR and VCD were the 
preferred regimens for clinical practice.
31
 
 
Table 3. Induction regimens. 
 
 
 
  
Figure 2. The initiation of most suitable and well-tolerable treatment in symptomatic, newly diagnosed MM 
patients involves the consideration of various factors, including whether this patient is a candidate for ASCT 
and presents with comorbidities, disability ... 
In patients who respond well and tolerate induction, initial therapy may be continued after stem cell 
collection, reserving ASCT for first relapse. This high efficacy of novel agents has, indeed, led 
some groups to investigate these agents upfront without ASCT: Len/Dex yielded similar survival 
rates at two years compared to Len/Dex and ASCT in a non-randomized ECOG-trial,
33
 although it 
had a number of shortcomings. This non-randomized comparative study included 290 patients who 
received IMiD-based initial therapy and early (n=173, 60%) or delayed (n=112, 40%) SCT. Both 
transplant options resulted in excellent survival regardless of the timing of transplantation (Table 
4),
29, 34–41
 but the inherent important limitations of these options requires that they be carefully 
discussed with ASCT candidates.
42
 In another non-randomized phase II trial of lenalidomide-
bortezomib-dexamethasone (RVD) induction, in which the choice of ASCT was left to the 
physician and patient, no difference in outcome was seen between the two approaches. However, 
since the choice of transplant was not prospective, also this study has to be interpreted with 
caution.
43
 Interestingly, the MRC-group has demonstrated that 42–58% of patients become minimal 
residual disease (MRD)-negative after ASCT and additional consolidation, arguing in favor of 
ASCT with an approximately 3-fold increase in MRD negativity,
44
 and suggesting that ASCT may 
only be postponed in those few patients achieving MRD-negativity with induction alone. Moreover, 
this study showed that MRD-negativity is different to IF-negative (IF) CR, since 14.5% of patients 
achieving IF-CR after ASCT had detectable MRD.
44
 Since CR achievement has been shown to 
correlate with OS, efforts to achieve MRD-negativity will continue and will fuel the search for the 
best approach from among different consolidation/maintenance strategies.
44
 Currently, there are 
only limited data of prospective studies comparing conventional chemotherapy plus novel agents to 
ASCT. The GIMEMA performed one prominent trial with 402 MM patients who received 4 cycles 
of Len/Dex (Rd) induction and were randomized to either 6 cycles of MPR or tandem-ASCT. This 
study reported a significantly improved PFS, but has not yet reported OS in the ASCT arm.
45
 Other 
ongoing trials are investigating the same burning issue, i.e. EMN, Intergroupe Francophone du 
Myelome (IFM), German Study Group MM (DSMM). 
 
Table 4. Results of large recent randomized studies in newly diagnosed myeloma. 
 
Interestingly, although OS is equivalent, regardless of whether ASCT is performed early or at the 
time of relapse,
46
 early transplantation is associated with improved time without symptoms, 
treatment and treatment-related adverse events and thus may often be preferred.
46
 Also of note, 
long-term follow up after ASCT was reported by the Spanish MM group with a median follow up 
of 153 months (12.8 years): 344 patients transplanted between 1989 and 1998 achieved an OS of 
35% in CR patients at 12 years, 22% in nearCR and 16% in VGPR and PR patients, suggesting that 
long-term MM control is attainable with ASCT and that in some patients with excellent response, 
even a cure can be obtained.
47
 That ASCT is a valid therapeutic option also in relapsed MM has 
also been shown in 200 patients undergoing retransplantation over a period of 15 years: PFS and 
OS were 15 and 42 months after ASCT, respectively, and factors associated with improved survival 
were an initial PFS of over 18 months after up-front ASCT, bortezomib- or lenalidomide-containing 
reinduction, response to reinduction and ISS stage I before ASCT.
48
 Ongoing large co-operative 
trials comparing effective induction combinations with and without ASCT are awaited and will 
clarify whether the timing of ASCT is relevant for survival, e.g. randomized trials of RVD or 
Len/Dex induction, with or without initial ASCT (European Myeloma Network (clinicaltrials.gov 
identifier:01208766), IFM together with a US consortium (Clinicaltrials.gov identifier:01208662), 
DSMM XIII (Clinicaltrials.gov identifier:01090089). 
Recommendation: novel-agent-based induction and up-front ASCT in medically fit patients lead to 
sustained remission and continues to be the standard of care in this patient cohort (1A). Current 
trials are investigating the role of novel agent combinations without up-front ASCT versus single- 
or tandem-ASCT. Induction therapy needs to include a triple combination of bortezomib with either 
adriamycin or thalidomide and dexamethasone (PAD or VTD; 1A), or with cyclophosphamide and 
dexamethasone (VCD; 2B). 
Allogeneic transplantation 
The role of allogeneic transplantation (allo-SCT) remains controversial due to the TRM (10–20%) 
and graft-versus-host disease (GvHD) rates even with non-myeloablative regimens. Therefore, allo-
SCT is considered investigational and actively pursued in clinical trials (DSMM, HOVON, 
GIMEMA, PETHEMA, EBMT, CIBMTR). Long-term follow up with 96 months from the 
European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell 
transplantation in MM (EBMT-NMAM200) study has recently been published: this trial 
prospectively compared tandem-autologous/reduced intensity (RIC) allogeneic transplantation 
(auto/RICallo) to ASCT alone in 357 patients up to the age of 69 years. Patients with HLA-identical 
siblings were allocated to auto/RICallo (n=108) and those without to ASCT (n=249). At 96 months, 
PFS and OS were 22% and 49% versus 12% (P=0.027) and 36% (P=0.03) with auto/RICallo and 
ASCT, respectively. In patients with del(13) abnormalities, corresponding PFS and OS were 21% 
and 47% versus 5% (P=0.026) and 31% (P=0.154), respectively, suggesting that auto/RICallo can 
overcome the impact of del(13), although longer 5-year follow up is needed for the correct 
interpretation of the value of auto/RICallo.
49
 Recent results from the CIBMTR analysis assessing 
allo-SCT in 1207 MM patients showed projected 5-year PFS and OS of 14% (95%CI: 9–20%) and 
29% (95%CI: 23–35%), respectively; lower than in the EBMT-NMAM200 trial. Multivariate risk 
factors adversely affecting OS were increasing age, longer interval from diagnosis to transplantation 
and unrelated donor grafts.
50
 Even though the number of allo-SCT has increased at the EBMT 
centers, primarily in advanced/refractory disease, most patients are not currently enrolled in 
prospective trials. As for newly diagnosed patients, recent findings raise the question of whether 
allografting, performed early in the course of the disease, may benefit the very HR MM population 
where poor outcomes are observed even after the introduction of new drugs. In particular, young 
patients with ISS II and III associated with del 1p/1q gain, t(4;14), del(17p) or t(14;16), in whom 
projected 4-year PFS and OS do not exceed 11% and 33%, respectively,
51
 may potentially benefit 
from allo-SCT. 
Recommendation: currently, allo-SCT may be considered for young patients with HR disease who 
are willing to accept the TRM and investigational nature of this therapy for a chance of a better 
long-term survival (2B). Carefully designed studies with long-term follow up are important to prove 
that allo-SCT should not be abandoned in MM.
49
 
Consolidation and maintenance therapy following induction therapy or 
transplant 
A series of studies has explored the role of maintenance therapy, both following conventional 
chemotherapy and following ASCT. Earlier experiences with chemotherapy were disappointing, the 
benefit of corticosteroids as single-drug maintenance was questionable and meta-analyses of 
interferon-α have shown positive effects but at the cost of problems of tolerability.1 Thalidomide 
has been shown to increase PFS after conventional therapy and ASCT. However, results have 
shown high rates of discontinuation due to toxicity and in HR MM has been described as 
detrimental in some studies:
52
 the MRC study assessed thalidomide maintenance in 820 newly 
diagnosed patients and determined that the median PFS was significantly longer with thalidomide 
(P<0.001), whereas OS was similar with and without maintenance (P=0.40). Patients with favorable 
interphase FISH (iFISH) showed improved PFS (P=0.004) and trend toward a late survival benefit, 
whereas patients with adverse iFISH showed no PFS benefit and worse OS (P=0.009).
53
 Similar 
results were reported from the Canadian group in 332 patients receiving TD ver;sus no 
consolidation with improvement of the duration of disease control, but worsening of patient 
reported QoL and no detectable OS benefit with TD.
54
 
Randomized controlled trials of maintenance lenalidomide following conventional therapy or ASCT 
have also been performed: in the randomized MM015 trial using MPR-R, MPR or MP, PFS was 
improved with 31 versus 14 and 13 months, respectively.
55
 The IFM and CALGB performed the 
ASCT trials with lenalidomide maintenance compared to placebo.
56,57
 Both trials demonstrated a 
doubling of the PFS from approximately two to four years; the CALGB trial also demonstrated an 
OS benefit. However, the risk of second primary malignancies (SPMs) increased approximately 2-
fold in the lenalidomide maintenance arm, although absolute event rates remained fairly small 
(~8%), and, despite the inclusion of SPMs as events, lenalidomide maintenance still resulted in 
improved EFS. Currently discussed issues of these trials are that patients in the control arm lacked 
uniform access to the active drug (thalidomide or lenalidomide) at relapse, and it is unclear whether 
the PFS improvement will be neutralized, since patients in the control arm can initiate the same 
therapy at the time of first relapse. Moreover, thalidomide might also potentiate solid SPMs, 
suggesting an IMiD class effect associated with melphalan exposure.
58
 Currently, the issue of SPMs 
is under investigation to determine disease-, therapy- and patient-specific risks, and we are waiting 
for the OS benefit in all three maintenance trials to mature before routine lenalidomide is 
recommended. 
Bortezomib administered every other week post ASCT has been shown to induce better OS than 
thalidomide maintenance,
35
 and this is currently being assessed in various trials (Nordic Myeloma 
Study Group, DSMM, IFM). Patients with del(17p13) benefited most from the bortezomib-
containing treatment before and after ASCT, suggesting that long-term administration of 
bortezomib may be recommended for patients with del(17p13).
28
 Bortezomib consolidation after 
ASCT has also been analyzed in 370 patients randomized to 20 doses of bortezomib versus no 
consolidation showing an improved PFS of 27 versus 20 months (P=0.05). Although no difference 
in OS was observed, this study suggests that consolidation may be beneficial in patients not 
achieving at least VGPR, but not with more than VGPR after ASCT.
59
 In a randomized, phase III 
study, comparing bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-
dexamethasone (TD) as induction for newly diagnosed, transplant-eligible patients, the same triplet 
or doublet regimens were planned as two 35-day cycles of consolidation after double-ASCT. In 
comparison with TD, the rate of CR (47% vs. 61%; P=0.012) and CR/nCR (61% vs. 73%; P=0.020) 
was significantly higher after VTD consolidation. Overall, VTD offered a 30.5% probability of up-
grading the response from less than CR before consolidation to CR after consolidation. With a 
median follow up of 30.4 months from start of consolidation, PFS at three years was significantly 
longer for the VTD compared to TD (60% vs. 48%; P=0.042). Patients who did not achieve CR 
(HR 0.59; P=0.037) and CR/nCR (HR 0.49; P=0.018) after double-ASCT most benefited from VTD 
consolidation.
29
 Combination maintenance with bortezomib plus thalidomide (VT) or bortezomib 
plus prednisone (VP) in elderly patients has demonstrated a better PFS for VT (39 months) than VP 
(32 months) and OS was longer with VT (5-year OS 69% vs. 50%), although these differences did 
not reach significance.
60
 Nevertheless, these results suggest that VP is the preferred maintenance 
approach for elderly patients because of the lesser side effects. These results of maintenance or 
consolidation trials should be discussed with the patient, especially in those with suboptimal 
response to ASCT or HR disease, and a bortezomib-based maintenance or clinical trial might be 
recommended.
28,59,60
 
Recommendation: thalidomide (1B) or lenalidomide (1A) maintenance post ASCT increases PFS 
and possibly OS (2A). Bortezomib-based regimens are a valuable treatment option, especially for 
patients who failed VGPR or CR/nCR after ASCT (2A). 
Options for initial treatment in patients not eligible for transplant 
For patients not eligible for transplant, randomized controlled trials have demonstrated that the 
addition of a novel agent to melphalan and prednisone (MP) results in improved outcomes. The 
meta analysis of 6 MPT versus MP trials demonstrated improved PFS and OS in some, but also 
increased toxicity with MPT. Similarly, VMP versus MP has resulted in a PR or better in 71% 
versus 35%, respectively, with a hazard ratio for OS clearly favoring bortezomib (0.61; P=0.008). 
Therefore, patients with newly diagnosed MM who are not candidates for ASCT due to age, 
comorbidities, impaired fitness or preference, may receive MPT or VMP (Table 3). MP may still 
have a role in elderly patients in whom therapy with MPT or VMP is not considered safe or 
feasible. MPR (without lenalidomide maintenance) does not improve PFS or OS compared with MP 
alone,
55
 but is currently being compared to MPT in an ECOG randomized trial (E1A06), the results 
of which are eagerly awaited. 
Interestingly, age, formerly used as the discriminator for choosing treatment, is considered of lesser 
importance today as compared to a careful geriatric assessment (GA) to define fit versus unfit 
patients and consequently select and/or dose-reduce therapy.
61,62
 Important comorbidity factors 
seem to be the Karnofsky Performance Status (KPS) and organ impairment (specifically lung and 
renal). Comorbidity scores, such as the Freiburg Comorbidity Index (FCI) or others (HCT-CI, 
Charlson Comorbidity Index; Kaplan Feinstein) are currently assessed, as well as the significance of 
locomotion (timed ‘up and go’ test) and impaired IADL (instrumental activities of daily living).61,62 
A therapeutic algorithm for newly diagnosed MM patients based on fitness and a defined GA 
testing may be better than age alone to identify patients who can be considered for reduced intensity 
ASCT, novel agent combination or only two-drug combinations (Figure 2).
61–63
 Unfortunately, the 
various options in elderly patients have not been compared in adequately powered clinical trials 
with relevant end points to determine best treatment strategies, although useful dose-adjustment 
recommendations have been published, alongside guidelines as to how to treat elderly MM 
patients.
63–65
 
Recommendations: VMP or MPT are the standards of care for transplant-ineligible patients (1A). 
Due to its excellent tolerability, lesser induction of polyneuropathy (PNP) and longer therapy 
endurance, weekly bortezomib schedules are preferred, especially in elderly, unfit or frail patients 
(2B). MPR+R increases PFS, but OS data are needed. Rd is also an effective option for these 
patients (2B). 
Optimal management of myeloma-related bone disease 
High potency intravenous bisphosphonates are a critical component of supportive care and have 
been shown to reduce skeletal-related events (SRE). Both pamidronate (PAM) and zoledronic acid 
(ZOL) are effective at reducing SRE in MM patients.
66,67
 ZOL has an increased risk of adverse 
renal toxicity. The UK MRC IX trial randomized patients to ZOL or clodronate (CLO) regardless of 
the presence of radiographically detected bone disease and reported a 5.5 month increase in median 
OS.
68
 This survival improvement was independent of SRE, suggesting that bisphosphonates have 
anti-myeloma properties. In the follow-up report of patients treated for more than two years, ZOL 
improved OS compared to CLO (P=0.02) and disease progression (P=0.03), suggesting that ZOL 
can be given over prolonged treatment periods and anti-myeloma properties are induced.
69
 At 
present, intravenous bisphosphonates are recommended for all MM patients requiring therapy, 
which should be continued with active disease and reassumed after disease relapse (1A).
70
 It is 
important to note that denosumab, a monoclonal antibody to RANK-ligand approved for use in 
breast and prostate cancer metastatic to bone, is currently being tested in a large randomized trial 
against ZOL, because the smaller randomized trial in fewer than 200 MM patients of denosumab 
versus ZOL showed an inferior survival in the subset of MM patients treated with denosumab.
71
 
The currently available data, therefore, do not yet support the use of denosumab for the treatment of 
myeloma-related bone disease. 
Management and treatment of toxicity 
Both IMiDs and proteasome inhibitors are associated with unique toxicities that require specific 
management. IMiDs, when combined with steroids or anthracyclines result in a marked increase in 
venous thromboembolic events. The rate of VTE in these regimens ranges from 20–40% without 
prophylaxis. A randomized trial of aspirin (100 mg/day), mini-dose warfarin (1.25 mg/day) and 
enoxaparin (40 mg s.c. daily) in patients receiving thalidomide-based regimens demonstrated 
equivalence between aspirin and mini-dose warfarin, whereas enoxaparin was more efficacious in 
preventing thrombotic events and should be used for patients at high-risk of thrombosis (1A).
72
 
Patients with MM are also at increased risk of infections as a consequence of disease-related 
immunodeficiency as well as anti-myeloma therapies.
15
 Traditional high-dose dexamethasone-based 
regimens increased infectious risks compared to low-dose dexamethasone.
33
 Antibacterial 
prophylaxis is commonly included in dexamethasone-containing and multi-agent regimens.
64
 
Bortezomib-based regimens are associated with varicella zoster reactivation rates that are nearly 
eliminated with acyclovir prophylaxis.
15,73
 For patients with recurrent, severe bacterial infections, 
intravenous immune globulin can be effective.
65
 
Peripheral neuropathy (PNP) is an important toxicity of both thalidomide and bortezomib occurring 
in approximately 50% of patients.
74
 PNP from thalidomide is cumulative, dose dependent and 
usually permanent. Bortezomib neuropathy is related to dose, schedule and mode of administration 
and is mostly reversible. Careful attention to the development of PNP is essential while patients are 
on therapy, and prompt dose reductions are required with development of neuropathy of any grade 
with thalidomide. A randomized trial of subcutaneous administration compared to intravenous 
administration of bortezomib showed a dramatic decrease in PNP of all grades (38% vs. 53%) and 
grade 3 or 4 (6% vs.16%), leading to its universal use and substantially improved tolerance and 
therapy endurance of bortezomib (2A).
75,76
 
SPMs have attracted attention after recent randomized trials consistently demonstrated more 
hematologic malignancies in patients treated with lenalidomide (or thalidomide) than placebo 
maintenance. Most prior studies that have attempted to clarify the phenomenon of SPMs have, 
however, been restricted by small numbers of patients, inadequate follow up and limitations of 
ascertainment of SPMs. The aim of subsequent studies is to assess genetic risks, underlying 
MM/disease-, patient- and therapy-related risks, and to characterize the biological mechanisms in 
order to minimize SPMs,
77–80
 bearing in mind that SPMs may emerge as an important long-term 
sequela of continuous improvements in MM care, of more intensively performed treatment, and 
also because of the longevity with this disease. 
Unsolved and future issues 
The debate surrounding ASCT, including allo-SCT for HR, young, still chemo-responsive MM 
patients, also involves important advances in the understanding of the biology of the disease, 
including the complexity and dynamics of genomics.
81
 The concept of risk-adapted strategies relies 
on prognostic factors, such as ISS stage, chromosomal and genetic abnormalities or gene expression 
profiling, the combination of ISS and FISH or ISS and FCI, or other biological parameters (Table 
2). Currently, the Arkansas and Mayo groups are applying risk-adapted therapies with TT5 aimed at 
sustaining the duration of CR
10
 or using the mSMART algorithm to define standard, intermediate- 
or HR-disease and recommend treatment options according to these risk categories.
25
 Although 
neither of these approaches is based on results of phase III trials, nor is the mSMART algorithm 
evidence-based, these risk-adapted approaches need to be further tested. 
In addition to treatment response (where achievement of VGPR and CR has been shown to strongly 
correlate with improved outcomes), MRD status, gene expression profiling and refined bone 
evaluations are currently included in clinical trials as important prognostic parameters which need 
to be validated by clinical end points. Moreover, since several groups have demonstrated substantial 
genetic heterogeneity between MM patients,
82–85
 subclones, linear disease evolution, genetic 
instability and dynamics of clonal evolution, as well as profound changes in the BM 
microenvironment, are currently being evaluated by several groups.
86–89
 Intratumor genetic 
heterogeneity occurs in addition to intertumor heterogeneity and contributes to the emergence of 
drug resistance in HR MM. Given this, in conjunction with the MM cellular hierarchy and the BM 
microenvironment being altered during tumor progression, this makes targeting of both an attractive 
approach, and fuels the ongoing pursuit of in vitro assays and murine models as crucial steps 
forward.
89–92
 That clinical drug resistance is linked to interconvertible phenotypic and functional 
states of tumor-propagating cells has been described for MM subpopulations, where post-germinal 
pre-PCs are more quiescent, enriched in epigenetic regulators and 300-fold more drug-resistant than 
mature PCs, suggesting that these might be responsible for MRD, drug-resistant relapse and require 
development of alternative therapeutic strategies.
93
 Understanding genetic events in MM also 
involves clarification of the genetic predisposition of MGUS and MM.
94,95
 As the treatment 
armentarium has greatly increased in MM, the aim is to achieve higher response rates with lower 
toxicity, define most appropriate therapies for specific patient groups, and allow the pendulum to 
gradually shift from control to cure.
96
 
Conclusions 
The treatment paradigm for MM has evolved over the past 20 years resulting in substantial 
improvements in survival. This trend is expected to continue with agents approved for relapsed 
disease moving earlier into the disease course. In addition, new classes of drugs to combine with 
existing regimens are under development, notably monoclonal antibodies. 
Emerging therapies include next generation proteasome inhibitors, IMiDs, signal transduction 
modulators (perifosine), HDAC-inhibitors and targeted therapies (inhibitors of NF-kB, MAPK, 
HSP90, AKT).
97–99
 The majority of MM patients diagnosed today can expect to have disease 
control over long periods of time, with access to all available therapies. In the attempt to define the 
best therapeutic strategies, future trials should not only investigate prognostic parameters at 
diagnosis, but also evaluate disease response within the BM and extramedullary (EM) sites and 
assess the dynamics of clonal expansion of the disease. A major challenge remains that of 
developing effective therapies for HR MM, for elderly and frail patients, for those outside clinical 
trials, and for patients with extensively pre-treated, refractory or EM disease and plasma cell 
leukemia.
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